Iatrogenic EffectIATROPREVNCT05045235
Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk
An observational study of Iatrogenic Effect and Prescription, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Iatrogenic Effect, Prescription, Follow-up
- How many people
- 1,500 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2021to Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patient hospitalized in the geriatric medicine department with olymedicated drugs
Who may be able to join
- patient hospitalized in the geriatric medicine department
- Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization;
- Numerous therapeutic modifications (3 or more);
- Drug interaction or introction of a new drug with one or more drug interactions;
- Medicinal product with a narrow therapeutic marge drug requiring close monitoring.
Who cannot join
- patient non hospitalized in the geriatric medicine department
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk.
The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new organizations in the health sector, according to article 51. The objectives of this course are to improve the relevance of prescription in elderly people with multiple drugs as well as, the coordination of care between the city and the hospital through the sharing of information and the establishment of multi-professional consultations between the various care actors.
- Conditions
- Iatrogenic Effect, Prescription, Follow-up, Consultation
- Keywords
- iatrogenic, prescription, follow-up, consultation
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of side effect number in ederly with polymedicated drugs
Change of side effect number in ederly with polymedicated drugs
Measured: up to 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2021
- Study start1 Sep 2021
- Primary completion1 Sep 2025
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Iatrogenic EffectStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05045235
- Sponsor's protocol ID
- PI2021_843_0158
- Acronym
- IATROPREV
- Status last verified
- Nov 2025
- First submitted
- 7 Sep 2021
- Last updated
- 19 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk.
- ClinicalTrials.gov ID
- NCT05045235
- Acronym / sponsor ID
- IATROPREV / PI2021_843_0158
- Conditions
- Iatrogenic Effect, Prescription, Follow-up, Consultation
- Keywords
- iatrogenic, prescription, follow-up, consultation
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 1 Sep 2025 (actual)
- Study completion
- Dec 2025 (estimated)
- First posted
- 16 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new organizations in the health sector, according to article 51. The objectives of this course are to improve the relevance of prescription in elderly people with multiple drugs as well as, the coordination of care between the city and the hospital through the sharing of information and the establishment of multi-professional consultations between the various care actors.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patient hospitalized in the geriatric medicine department with olymedicated drugs
Key inclusion criteria (5 listed)
- patient hospitalized in the geriatric medicine department
- Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization;
- Numerous therapeutic modifications (3 or more);
- Drug interaction or introction of a new drug with one or more drug interactions;
- Medicinal product with a narrow therapeutic marge drug requiring close monitoring.
Key exclusion criteria (1 listed)
- patient non hospitalized in the geriatric medicine department
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change of side effect number in ederly with polymedicated drugs
Time frame: up to 4 years
Change of side effect number in ederly with polymedicated drugs
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Iatrogenic Effect
Not yet recruiting
BIS in ICU Interventional Study
Cardiac Surgical Procedures (Postoperative Population), Critical Illness
RecruitingObservational study
Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples Bank
Paediatric Malignancies
RecruitingPhase 3
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Pneumonia, Viral, Ventilator Associated Pneumonia
Enrolling by invitation
The Effect of Cognitive Behavioral Therapy
Intervention (Training) Condition
Active, not recruiting
Effect of Two Oral Care Methods on Oral Flora and VAP in Mechanically Ventilated Patients
Ventilator Associated Pneumonia ( VAP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Iatrogenic Effect and Prescription, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of side effect number in ederly with polymedicated drugs (time frame: up to 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2025.